首页> 外文期刊>Natural Products and Bioprospecting >Anti-leishmanial and Anti-inflammatory Agents from Endophytes: A Review
【24h】

Anti-leishmanial and Anti-inflammatory Agents from Endophytes: A Review

机译:内生细菌的抗利什曼肽和抗炎药:审查。

获取原文
       

摘要

Natural productshave and will continue to offer exceptional chemical diversity with a wide biological activities spectrum. They have been so far the most promising sources for drug discovery and development [1, 2]. According to Newman and Cragg [3] and Katz and Baltz [4], over 50% of all agents currently in clinical use are either natural products or natural product derived. The use of these products as medicines is ancient since for centuries, health practices have incorporated the medicinal properties of products from diverse sources, particularly microbial species. The modern discovery of penicillin and streptomycin led to the recognition of microbial natural products as one of the most powerful and prolific sources for drug lead discovery over the past seven decades [5]. Indeed, the rates of discovery for new drugs dramatically dropped since the year's nineties because many pharmaceutical companies stopped their natural products programmes in profit of high-throughput screening of synthetic chemicals [4].
机译:天然产物具有并将继续提供具有广泛生物活性谱的卓越化学多样性。迄今为止,它们一直是药物发现和开发的最有希望的来源[1、2]。根据Newman和Cragg [3]以及Katz和Baltz [4]的说法,目前临床使用的所有药物中有50%以上是天然产物或天然产物。数百年来,将这些产品用作药物一直是很古老的,健康实践已经吸收了来自各种来源(尤其是微生物物种)的产品的药用特性。在青霉素和链霉素的现代发现中,微生物天然产物已被公认为是过去七十年来发现药物线索的最有力和最多产的来源之一[5]。的确,自九十年代以来,新药的发现率急剧下降,因为许多制药公司为了获得高通量的合成化学品筛选而停止了其天然产品计划[4]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号